The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
GPR30 predicts poor survival for ovarian cancer
Open accessAbstract
Objectives GPR30 is a 7-transmembrane G protein-coupled estrogen receptor that functions alongside traditional estrogen receptors to regulate cellular responses to estrogen. Recent studies suggest that GPR30 expression is linked to lower survival rates in endometrial and breast cancer. This study was conducted to evaluate GPR30 expression in ovarian tumors. Methods GPR30 expression was analyzed using immunohistochemistry and archival specimens from 45 patients with ovarian tumors of low malignant potential (LMP) and 89 patients with epithelial ovarian cancer (EOC). Expression, defined as above or below the median (intensity times the percentage of positive epithelial cells) was correlated with predictors of adverse outcome and survival. Results GPR30 expression above the median was observed more frequently in EOC than in LMP tumors (48.3% vs. 20%, p= 0.002), and in EOC was associated with lower 5-yr survival rates (44.2% vs. 82.6%, Log rank p < 0.001). Tumor grade and FIGO stage, the other significant predictors of survival, were used to stratify cases into “high-risk” and “low risk” groups. The 5-yr survival rate for “low risk” EOC (all grade 1 and stage I/II, grade 2) was 100%. In “high risk” EOC (all grade 3 and stage III/IV, grade 2), the difference in 5-year survival by GPR 30 expression was significant (33.3% vs. 72.4%, p = 0.001). Conclusions The novel estrogen-responsive receptor GPR30 is preferentially expressed in “high risk” EOC and is associated with lower survival rates. Further investigation of GPR30 as a potential target for therapeutic intervention in high risk EOC is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302
Self-citationReeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Cited by
The G-protein-coupled estrogen receptor GPER in health and disease
Prossnitz, E. R., & Barton, M. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.122 · Cited by 925
Self-citationG protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Potential Mechanisms of Bisphenol A (BPA) Contributing to Human Disease
Cimmino, I., Fiory, F., Perruolo, G., Miele, C., Beguinot, F., Formisano, P., & Oriente, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165761 · Cited by 478
Estrogen biology: New insights into GPER function and clinical opportunities
Prossnitz, E. R., & Barton, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.02.002 · Cited by 400
Self-citationFilardo, E. J., & Thomas, P. (2012) · Endocrinology · doi:10.1210/en.2012-1061 · Cited by 366
Metadata
- Authors
- Smith, H. O., Arias-Pulido, H., Kuo, D. Y., Howard, T., Qualls, C. R., Lee, S.-J., Verschraegen, C. F., Hathaway, H. J., Joste, N. E., & Prossnitz, E. R.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 114
- Issue
- 3
- Pages
- 465-471
- ISSN
- 0090-8258 (ISSN-L)
- OpenAlex
- W1973853922
- Cited by
- 206
- References
- 2
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GPR30 predicts poor survival for ovarian cancer. https://app.cochat.ai/papers/10.1016/j.ygyno.2009.05.015
- The paper
- Smith, H. O., Arias-Pulido, H., Kuo, D. Y., Howard, T., Qualls, C. R., Lee, S.-J., Verschraegen, C. F., Hathaway, H. J., Joste, N. E., & Prossnitz, E. R. (2009). GPR30 predicts poor survival for ovarian cancer. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2009.05.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.